Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer

Metastatic Castrate- Resistant Prostate Cancer Clinical Trial

Official title:

Phase I Study of Idronoxil Combined With Radiation Treatment in Men With Metastatic Prostate Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03041285
• Other study ID #: NOX66 version 1
• Status: Terminated
• Phase: Phase 1
• Start date: August 31, 2017
• Est. completion date: September 17, 2019

Study information

• Verified date: May 2022
• Source: Royal North Shore Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to determine the toxicity of Idronoxil (NOX66) when used in combination with palliative radiotherapy for metastatic prostate cancer

Description:

Who is it for? Patient may be eligible for this study if they have late stage metastatic prostate cancer which is castrate resistant and have metastatic lesions that are suitable for radiotherapy. Study details There are two groups of patients in this study and no randomisation. The two groups will have two different doses of idronoxil (NOX66), representing a 2-step dose escalation. Both groups receive the same standard radiotherapy dose. Group 1 will receive the lower dose (400 mg) of idronoxil suppository daily and Group 2 800 mg daily. Recruitment into Group 2 will only commence once all Group 1 patients have completed the 13-day treatment course of idronoxil suppository without excessive unexpected toxicity. The total treatment duration will be 13-15 days for both groups depends on whether radiotherapy is given on consecutive days or over the weekend. Day 0: commence idronoxil (NOX66) Days 1-5: 1 or 2 lesions will receive 20 Gy (radiotherapy dose unit) radiotherapy in 5 daily fractionated doses and continue daily NOX66 Day 6-12: Continue NOX66 (the duration of NOX66 will be 13-15 days depends on whether radiotherapy is given on consecutive days or over the weekend). Both groups will have prostate-specific membrane antigen positron emission tomography (PSMA-PET) scans before starting treatment and three months after the last fraction of radiotherapy to assess treatment response.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: September 17, 2019
• Est. primary completion date: September 17, 2019
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Confirmed metastatic prostate cancer that is castrate-resistant.
• 2-3 lesions suitable for radiotherapy.
• ECOG Performance status 0-2.
• Adequate bone marrow, hepatic and renal function
• At least 4 weeks must have elapsed prior to commencement of idronoxil treatment since prior chemotherapy, investigational drug or biologic therapy

Exclusion Criteria:

• Chemotherapy regimens with delayed toxicity within the last 4 weeks.
• Any situation where the use of suppository therapy is contra-indicated or impractical(eg. chronic diarrhoea, colostomy, ulcerative colitis).
• No concurrent systemic chemotherapy or biologic therapy is allowed.
• Psychiatric disorder or social or geographic situation that would preclude study participation.
• Patient unable to provide consent

Related Conditions & MeSH terms

• Metastatic Castrate- Resistant Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• idronoxil (NOX66) suppository
Patients in Group 1 will be given 400mg of Idronoxil suppository (NOX66) (1 suppository) daily from Day 0(1 day before radiotherapy) until 7 days after radiotherapy. Group 2 will be given Idronoxil (NOX66) 800mg (2 suppositories) daily from Day 0 until 7 days after radiotherapy. All patients will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 fractions. Radiotherapy session will involve irradiation of 1-2 lesions. .

Radiation:
• Stereotactic Body Radiation Therapy
All patients (Group 1 and Group 2) will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 daily fractions on consecutive days. Radiotherapy session (week 1) will involve irradiation to 1-2 lesions.

Locations

Country	Name	City	State
Australia	Royal North Shore Hospital	St Leonards	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
Royal North Shore Hospital

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	safety of Idronoxil dose escalation	Toxicity and relationship with study drug NOX66 will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) V4.3	From start of NOX66 with stereotactic radiotherapy up to three months post treatment.
Secondary	evidence of clinical tumour response	PSMA-PET CT will be done before and 3 months after treatment. The change in SUV in PSMA PET will be used to assess tumour metabolic response.; Pre and post treatment tumour size on CT will be measured and RECIST criteria will be used to measure tumour response.	3 months post treatment